Cambrian BioPharma Inc 4
4 · Sensei Biotherapeutics, Inc. · Filed Dec 8, 2025
Insider Transaction Report
Form 4
Cambrian BioPharma Inc
10% Owner
Transactions
- Sale
Common Stock
2025-12-04$9.06/sh−5,000$45,300→ 177,654 total - Sale
Common Stock
2025-12-05$11.40/sh−14,508$165,391→ 163,146 total - Sale
Common Stock
2025-12-05$12.29/sh−1,745$21,446→ 161,401 total - Sale
Common Stock
2025-12-05$13.16/sh−42$553→ 161,359 total
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.00 to $9.54. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.
- [F3]These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
- [F4]The price reported in Column 4 is a weighted average price. The prices sold ranged from $11.00 to $12.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. The prices sold ranged from $12.02 to $12.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported in Column 4 is a weighted average price. The prices sold ranged from $13.00 to $13.26. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.